Frost lab interviewed by KENS5


http://www.kens5.com/news/health/breakthrough-drug-in-the-battle-against-alzheimers-disease/312724524

The Frost lab was interviewed by San Antonio news station KENS5 to comment on the results from Biogen's phase 1b clinical trials with the drug Aducanumab, a monoclonal antibody that targets Amyloid beta aggregates.

The Frost lab was not involved in the study.

Alzforum has a nice write-up about Aducanumab: http://www.alzforum.org/therapeutics/aducanumab

Stay up to date on the progress of Aducanumab clinical trials: https://clinicaltrials.gov/ct2/results?term=BIIB037&Search=Search